Article
Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden.
Cancer immunology, immunotherapy : CII - 1 Aug 2021
Salehi-Rad Ramin, Li Rui, Tran Linh M, Lim Raymond J, Abascal Jensen, Momcilovic Milica, Park Stacy J, Ong Stephanie L, Shabihkhani Maryam, Huang Zi Ling, Paul Manash, Shackelford David B, Krysan Kostyantyn, Liu Bin, Dubinett Steven M
Abstract excerpt
Conditional genetically engineered mouse models (GEMMs) of non-small cell lung cancer (NSCLC) harbor common oncogenic driver mutations of the disease, but in contrast to human NSCLC these models possess low tumor mutational burden (TMB). As a result, these models often lack tumor antigens that can elicit host adaptive immune responses, which limits their utility in immunotherapy studies. Here, we establish...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.